Shoreline Biosciences
N. Max Schabla, Ph.D., is a skilled scientist currently serving as Scientist II at Shoreline Biosciences, Inc., a position held since April 2021, after previously holding the role of Scientist I. Prior to this, N. Max Schabla contributed to Creighton University School of Medicine as a Postdoctoral Researcher and Technical Director of the Flow Cytometry Core Facility from July 2019 to April 2021. Additionally, N. Max Schabla served as a part-time instructor in immunology at the University of Nebraska at Omaha from January 2020 to May 2020.
Shoreline Biosciences
Shoreline's proprietary cell therapy technology platform is based on deep expertise in iPSC differentiation methods and genetic programming of the IL-15/CISH pathway for enhanced metabolic fitness and persistence of the engineered NK Cells to improve anti-cancer activity.